Improve Human Health to Preserve Patients’ Dignity
Leading the advancement of innovative therapies in genitourinary tumors and women's health
Products
Vesique®(APL-1202) | Cevira® (APL-1702)
Core Areas
News & Updates
Blue Light Cystoscopy System Approved for Marketing in China; “Blue Light Era” for Precision Treatment of Bladder Cancer Begins
[April 24, Beijing] Recently, SYSTEM BLUE, a blue light cystoscopy system from Richard Wolf GmbH (a partner of Asieris Pharmaceuticals), received marketing approval from the
Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth
Shanghai, China, April 17, 2026 – Asieris Pharmaceuticals today released its 2025 Annual Report. Highlights include strong progress under its Commercialization 2.0 strategy, continued commercial
Cevira® Endorsed with Level 1A Evidence in Expert Consensus, Establishing a New Benchmark for Non-Invasive Treatment of Cervical Precancerous Lesions
A new expert consensus on photodynamic therapy (PDT) for cervical squamous intraepithelial lesions (SIL) has been officially issued by the Chinese Society of Colposcopy and
Asieris and SPH Kyuan Trade Announce Import and Distribution Strategic Partnership to Accelerate the Commercialization of Cevira®
Shanghai, China, March 24, 2026 – Asieris Pharmaceuticals (688176.SH) today announced a strategic partnership with Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd. (SPH Kyuan
Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
China, March, 3, 2026 — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women’s health, announced today that
Asieris Announces European Medicines Agency Accepts Marketing Authorization Application for APL-1702
SHANGHAI, China, February 27, 2026 — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company specializing in genitourinary tumors and women’s health, announced today
